請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30158
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴信志,薛博仁 | |
dc.contributor.author | Shu-Kuan Wang | en |
dc.contributor.author | 王淑寬 | zh_TW |
dc.date.accessioned | 2021-06-13T01:40:12Z | - |
dc.date.available | 2009-07-20 | |
dc.date.copyright | 2007-07-20 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-12 | |
dc.identifier.citation | Alangaden, G. J., Manavathu, E. K., Vakulenko, S. B., Zvonok, N. M. & Lerner, S. A. (1995). Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 39, 1700-1703.
Aubry, A., Veziris, N., Cambau, E., Truffot-Pernot, C., Jarlier, V. & Fisher, L. M. (2006). Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50, 104-112. Balabanova, Y., Ruddy, M., Hubb, J., Yates, M., Malomanova, N., Fedorin, I. & Drobniewski, F. (2005). Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 24, 136-139. Balasubramanian, V., Wiegeshaus, E. H., Taylor, B. T. & Smith, D. W. (1994). Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 75, 168-178. Barnes, P. F. & Cave, M. D. (2003). Molecular epidemiology of tuberculosis. N Engl J Med 349, 1149-1156. Bartlett, J. G., Dowell, S. F., Mandell, L. A., File Jr, T. M., Musher, D. M. & Fine, M. J. (2000). Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31, 347-382. Berning, S. E. (2001). The role of fluoroquinolones in tuberculosis today. Drugs 61, 9-18. Blondeau, J. M. (2004). Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 49 Suppl 2, S73-78. Bozdogan, B. & Appelbaum, P. C. (2004). Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23, 113-119. Bozeman, L., Burman, W., Metchock, B., Welch, L. & Weiner, M. (2005). Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 40, 386-391. Burman, W. J., Goldberg, S., Johnson, J. L. & other authors (2006). Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174, 331-338. Canetti, G., Froman, S., Grosset, J., Hauduroy, P., Langerova, M., Mahler, H. T., Meissner, G., Mitchison, D. A. & Sula, L. (1963). Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bulletin of the World Health Organization 29, 565-578. Cave, M. D., Eisenach, K. D., McDermott, P. F., Bates, J. H. & Crawford, J. T. (1991). IS6110: conservation of sequence in the Mycobacterium tuberculosis complex and its utilization in DNA fingerprinting. Mol Cell Probes 5, 73-80. CDC (1991). Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 40, 585-591. CDC, T. (2005). Statistics of Communicable Disease. Cole, E., McMurray,Jacobs,et al. (2004). Tuberculosis and the Tubercle Bacillus. Cole, S. T., Brosch, R., Parkhill, J. & other authors (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544. Collins, C. H. & Uttley, A. H. (1985). In-vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 16, 575-580. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & Dye, C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163, 1009-1021. Cox, H. S., Kubica, T., Doshetov, D., Kebede, Y., Rusch-Gerdess, S. & Niemann, S. (2005). The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 6, 134. Crofton J, C. P., Maher D. (1997). Guidelines for the management of drug-resistant tuberculosis. WHO/TB, 96-210. De Rossi, E., Blokpoel, M. C., Cantoni, R., Branzoni, M., Riccardi, G., Young, D. B., De Smet, K. A. & Ciferri, O. (1998). Molecular cloning and functional analysis of a novel tetracycline resistance determinant, tet(V), from Mycobacterium smegmatis. Antimicrob Agents Chemother 42, 1931-1937. De Rossi, E., Arrigo, P., Bellinzoni, M., Silva, P. A., Martin, C., Ainsa, J. A., Guglierame, P. & Riccardi, G. (2002). The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med 8, 714-724. De Rossi, E., Ainsa, J. A. & Riccardi, G. (2006). Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30, 36-52. Doucet-Populaire, F., Buriankova, K., Weiser, J. & Pernodet, J. L. (2002). Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2, 355-370. Dye, C., Watt, C. J. & Bleed, D. (2002). Low access to a highly effective therapy: a challenge for international tuberculosis control. Bulletin of the World Health Organization 80, 437-444. Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M. & Dooley, S. W. (1993). The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328, 521-526. Gillespie, S. H. & Kennedy, N. (1998). Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 2, 265-271. Gillespie, S. H. & Billington, O. (1999). Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 44, 393-395. Ginsburg, A. S., Grosset, J. H. & Bishai, W. R. (2003a). Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3, 432-442. Ginsburg, A. S., Woolwine, S. C., Hooper, N., Benjamin, W. H., Jr., Bishai, W. R., Dorman, S. E. & Sterling, T. R. (2003b). The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 349, 1977-1978. Goyal, M., Saunders, N. A., van Embden, J. D., Young, D. B. & Shaw, R. J. (1997). Differentiation of Mycobacterium tuberculosis isolates by spoligotyping and IS6110 restriction fragment length polymorphism. J Clin Microbiol 35, 647-651. Grimaldo, E. R., Tupasi, T. E., Rivera, A. B., Quelapio, M. I., Cardano, R. C., Derilo, J. O. & Belen, V. A. (2001). Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 5, 546-550. Hawkey, P. M. (2003). Mechanisms of quinolone action and microbial response. The Journal of antimicrobial chemotherapy 51 Suppl 1, 29-35. Hegde, S. S., Vetting, M. W., Roderick, S. L., Mitchenall, L. A., Maxwell, A., Takiff, H. E. & Blanchard, J. S. (2005). A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308, 1480-1483. Hirano, K., Aono, A., Takahashi, M. & Abe, C. (2004). Mutations including IS6110 insertion in the gene encoding the MPB64 protein of Capilia TB-negative Mycobacterium tuberculosis isolates. J Clin Microbiol 42, 390-392. Hsueh, P. R., Liu, Y. C., So, J., Liu, C. Y., Yang, P. C. & Luh, K. T. (2006). Mycobacterium tuberculosis in Taiwan. J Infect 52, 77-85. Huang, T. S., Kunin, C. M., Shin-Jung Lee, S., Chen, Y. S., Tu, H. Z. & Liu, Y. C. (2005). Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 56, 1058-1062. Infectious Diseases Society of the Republic of China;The Society of Tuberculosis, T. (2004). Guidelines for chemotherapy of tuberculosis in Taiwan. J Microbiol Immunol Infect 37, 382-384. Ji, B., Lounis, N., Maslo, C., Truffot-Pernot, C., Bonnafous, P. & Grosset, J. (1998). In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42, 2066-2069. Jindani, A., Aber, V. R., Edwards, E. A. & Mitchison, D. A. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121, 939-949. Jones, B. E., Young, S. M., Antoniskis, D., Davidson, P. T., Kramer, F. & Barnes, P. F. (1993). Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148, 1292-1297. Jou, R., Chiang, C. Y. & Huang, W. L. (2005). Distribution of the Beijing family genotypes of Mycobacterium tuberculosis in Taiwan. J Clin Microbiol 43, 95-100. Kamerbeek, J., Schouls, L., Kolk, A. & other authors (1997). Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35, 907-914. Kent PT, K. G. (1985). Public Health Mycobacteriology: A Guide for the Level III Laboratory. CDC. Kocagoz, T., Hackbarth, C. J., Unsal, I., Rosenberg, E. Y., Nikaido, H. & Chambers, H. F. (1996). Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 40, 1768-1774. Koksal, D., Unsal, E., Poyraz, B., Kaya, A., Savas, H., Sipit, T. & Gonullu, U. (2006). The value of serum interferon-gamma level in the differential diagnosis of active and inactive pulmonary tuberculosis. Tuberk Toraks 54, 17-21. Lounis, N., Ji, B., Truffot-Pernot, C. & Grosset, J. (1997). Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 41, 607-610. Lounis, N., Bentoucha, A., Truffot-Pernot, C., Ji, B., O'Brien, R. J., Vernon, A., Roscigno, G. & Grosset, J. (2001). Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 45, 3482-3486. Mazurek, G. H. & Villarino, M. E. (2003). Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 52, 15-18. McKeegan, K. S., Borges-Walmsley, M. I. & Walmsley, A. R. (2003). The structure and function of drug pumps: an update. Trends Microbiol 11, 21-29. Miesel, L., Greene, J. & Black, T. A. (2003). Genetic strategies for antibacterial drug discovery. Nat Rev Genet 4, 442-456. Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E. & Bishai, W. R. (1999). Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43, 85-89. Montero, C., Mateu, G., Rodriguez, R. & Takiff, H. (2001). Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 45, 3387-3392. NCCLS (2003). Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes: Approved Standard. NCCLS document M24-A. Nikonenko, B. V., Samala, R., Einck, L. & Nacy, C. A. (2004). Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48, 4550-4555. Papastavros, T., Dolovich, L. R., Holbrook, A., Whitehead, L. & Loeb, M. (2002). Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Cmaj 167, 131-136. Pasca, M. R., Guglierame, P., Arcesi, F., Bellinzoni, M., De Rossi, E. & Riccardi, G. (2004). Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 48, 3175-3178. Patrick R. MuPRAY, E. J. B., James H. JORGENSEN, Michael A.PFAller, Robert H. Yolken (2006). Manual of Clinical Microbiology 8th Edition Perlman, D. C., El Sadr, W. M., Heifets, L. B. & other authors (1997). Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. Aids 11, 1473-1478. Reichman, L. B. & Mangura, B. T. (2005). And the beat goes on. Am J Respir Crit Care Med 172, 140; author reply 140. Richeldi, L., Covi, M., Ferrara, G., Franco, F., Vailati, P., Meschiari, E., Fabbri, L. M. & Velluti, G. (2002). Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. Monaldi Arch Chest Dis 57, 39-43. Riley, L. W. (2006). Of mice, men, and elephants: Mycobacterium tuberculosis cell envelope lipids and pathogenesis. J Clin Invest 116, 1475-1478. Rodriguez, J. C., Ruiz, M., Lopez, M. & Royo, G. (2002). In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 20, 464-467. Rusch-Gerdes, S., Pfyffer, G. E., Casal, M., Chadwick, M. & Siddiqi, S. (2006). Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44, 688-692. Saito, H., Sato, K., Tomioka, H. & Dekio, S. (1995). In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber Lung Dis 76, 377-380. Sbarbaro, J. A., Iseman, M. D. & Crowle, A. J. (1996). Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis 77, 491-495. Shamputa, I. C., Rigouts And, L. & Portaels, F. (2004). Molecular genetic methods for diagnosis and antibiotic resistance detection of mycobacteria from clinical specimens. Apmis 112, 728-752. Sharma, S. K. & Mohan, A. (2004). Multidrug-resistant tuberculosis. Indian J Med Res 120, 354-376. Siddiqi, N., Das, R., Pathak, N., Banerjee, S., Ahmed, N., Katoch, V. M. & Hasnain, S. E. (2004). Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 32, 109-111. Smith, I. (2003). Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 16, 463-496. Sullivan, E. A., Kreiswirth, B. N., Palumbo, L., Kapur, V., Musser, J. M., Ebrahimzadeh, A. & Frieden, T. R. (1995). Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345, 1148-1150. Szabo, D., Keyzer, H., Kaiser, H. E. & Molnar, J. (2000). Reversal of multidrug resistance of tumor cells. Anticancer Res 20, 4261-4274. Takiff, H. E., Salazar, L., Guerrero, C., Philipp, W., Huang, W. M., Kreiswirth, B., Cole, S. T., Jacobs, W. R., Jr. & Telenti, A. (1994). Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38, 773-780. Takiff, H. E., Cimino, M., Musso, M. C., Weisbrod, T., Martinez, R., Delgado, M. B., Salazar, L., Bloom, B. R. & Jacobs, W. R., Jr. (1996). Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci U S A 93, 362-366. Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M. J., Matter, L., Schopfer, K. & Bodmer, T. (1993). Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647-650. Tomioka, H., Sato, K., Shimizu, T. & Sano, C. (2002). Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. J Infect 44, 160-165. van Rie, A., Victor, T. C., Richardson, M. & other authors (2005). Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 172, 636-642. Victor, T. C., van Helden, P. D. & Warren, R. (2002). Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life 53, 231-237. Wang, J. Y., Lee, L. N., Chou, C. S., Huang, C. Y., Wang, S. K., Lai, H. C., Hsueh, P. R. & Luh, K. T. (2004). Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 42, 4599-4603. Wang, J. Y., Hsueh, P. R., Lee, L. N., Liaw, Y. S., Shau, W. Y., Yang, P. C. & Luh, K. T. (2005). Mycobacterium tuberculosis inducing disseminated intravascular coagulation. Thromb Haemost 93, 729-734. Wang, J. Y., Hsueh, P. R., Jan, I. S., Lee, L. N., Liaw, Y. S., Yang, P. C. & Luh, K. T. (2006). Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61, 903-908. Wang, J. Y., Lee, L. N., Lai, H. C., Wang, S. K., Jan, I. S., Yu, C. J., Hsueh, P. R. & Yang, P. C. (2007). Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59, 860-865. Warren, R. M., Victor, T. C., Streicher, E. M., Richardson, M., Beyers, N., Gey van Pittius, N. C. & van Helden, P. D. (2004). Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 169, 610-614. WHO (2003). Global Tuberculosis Control: Surveillance, Planning, Financing.. WHO/TB 316. Zhao, X. & Drlica, K. (2002). Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185, 561-565. Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A., Ramaswamy, S., Domagala, J., Musser, J. M. & Drlica, K. (2000). Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 182, 517-525. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/30158 | - |
dc.description.abstract | 結核病(tuberculosis , TB)仍是現今影響全球人類健康的重要疾病,由於缺乏新的藥,以及有多重藥物呈抗藥性的菌株(MDRTB-是指同時對 isoniazid和rifampin第一線藥物呈抗藥性的M.tuberculosis)存在,使得每年有800-900萬人新感染TB,以及每年有200-300萬人死於TB。目前估計全世界約有三分之一人口感染TB。Fluoroquinolones(FQs)是抗TB的新藥。由於其副作用的毒性較低,藥效持久,且是在生物體內和體外對Mycobacterium tuberculosis(MTB)都有良好活性的廣效性口服藥物,因此已經用於預防和治療MDRTB的病人或對第一線用藥有不適應症的病人。自1986年以來FQs已用於治療社區感染的一般傳染性疾病,然而近年來卻已發現有MTB可能在短短7天的單一FQs處方用藥而產生抗藥性的情形 (NEJM 349;20, 2003) 。因為TB是一傳染性疾病,抗藥性的增加對於防疫工作政策是非常急迫,因此必須密切注意FQs對MTB藥物感受性的發展。過去所知道的資訊都是針對抗TB的第一線用藥,而抗TB的新藥FQs的有關數據在台灣仍然很有限,因此,本篇論文的主題是探討FQs在台大醫院分離菌株中的抗藥情形,與TB病人中同時對第一線用藥呈抗藥性;或是MDRTB病人;或過去用過抗TB的藥物;或使用過FQs治療病人的相關數據。
從2004-2005年間抽樣420株臨床分離的MTB菌,來自420位病人。先確定第一線用藥的藥物感受性和FQs的最小抑制濃度MIC分析與MDRTB的相關性;進一步分析FQs抗藥性決定基因gyrase 在QRDRs(quinolones resistance-determining regions)是否發生突變;與FQs抗藥性以及MDRTB的關係;再進行genotyping(spoligotyping)的分析,是否有菌株的散布或群聚。結果顯示:420株中對第一線用藥 isoniazid,rifampin,ethambutol,或對任何一種呈抗藥性,以及是MDR的比例分別是12.4, 6.2, 6.2, 17.1和5.0(%);對FQs藥物ofloxacin,ciprofloxacin,levofloxacin,moxifloxacin的感受性分別是98.3, 98.6, 98.6, 97.6(%)。抗藥的原因發生在QRDRs GyrA 基因是A90V和 D94G的突變(35.7%),在GyrB基因是N538D的突變(7.1%)。整體而言FQs的抗藥性在台大醫院的檢體中為3.3%,發生在QRDR的比率是42.8%。而spoligotyping顯示北京株佔42.8%,在 MDR 和FQR的菌株中都比在具感受性的菌株中佔較高的比率。對FQ呈抗藥性者與過去是否接觸抗TB藥物或對第一線藥物呈抗藥性有明顯相關,但是其間的抗藥機制並不相同,為何會有相關?在本論文中推測可能與病人的免疫力情況有關。對第一線用藥呈抗藥性或MDRTB病人,或過去用過抗TB藥物的病人,細菌在其體內比較佔優勢,MTB菌有時間活化efflux pump並將藥物排出菌體外,以及製造特殊蛋白抑制藥物的作用。或也可能是藥物的不適當使用有關,文獻上指出,治療TB不能用單一處方,因此,建議在臨床使用FQ藥物前應先檢測其藥敏試驗,並謹慎選用,以免提早產生對FQs呈抗藥性的菌株,徒增防疫工作的負擔。未來除了繼續評估抗藥性的發展,應積極開發快速的檢測抗藥性的方法,俾能儘早提供臨床醫師正確的診斷,以免延誤治療,製造讓細菌產生抗藥性的機會 | zh_TW |
dc.description.abstract | Tuberculosis (TB), due to lack of new medicine to cure and the existence of MDRTB (multi-drugs resistance tuberculosis, resistance to both isoniazid and rifampin in M. tuberculosis) , remains as a vital disease threatening human health globally, causing around 8 to 9 million people being newly affected and dead at the number of 2 to 3 million annually. It is currently estimated that one third of people are suffering from this disease. Fluoroquinolones (FQs) are the new agents to anti M. tuberculosis (MTB), with its low side-effects, toxicities and good activities in vitro and vivo, FQs have been used to prevent and treat MDRTB, and are applied to test the agent tolerance of the first line patients. Backing in 1986, FQs have been used to treat the community-acquired infections, but until recent years, the situation of new anti-drug (NEJM 349;20,2003) on FQs prescription of MTB within a short period of seven days was noticed. In view that TB is an infectious disease, it is crucial to implement an urgent epidemic prevention, and take a close watch on the development of FQs vs. MTB. The previous information we have is limited on the anti-TB in first line usage, with little data on related FQs against TB. It is therefore, the purpose of this study is to investigate the anti-TB on clinical isolates of FQs used in NTUH as well as the drug resistance by the first line TB patients or MDRTB patients and also to study the data relevance of patients of past history.
A total of of 420 clinical isolates of M. tuberculosis were randomly selected during 2004 to 2005 to determine the minimal inhibitory concentrantion (MICs) of FQs. We amplified the subunit of DNA gyrase quinolones resistance-determining regions (QRDR) by PCR and compared the nucleotide-sequences of the FQs resistance with that of the susceptible isolates followed by the analysis of genotyping (spoligotyping) to see its community scattering against clinical isolates. The resistance to isoniazid, rifampin, ethambutol, any one drug, and multi-drugs were 12.4, 6.2, 6.2, 17.1 and 5.0 (%) respectively; susceptibility to ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin in FQs at 98.8, 98.6, 98.6, 97.6 (%) respectively. The reason of resistance lies in QRDRs GyrA being the acquired genetic mutation of A90V and D94G (35.7%), and GyrB being the acquired genetic mutation of N538D (7.1%). Generally speaking, the FQs resistance held in NTUH is 3.3% as compared to 19% of that in MDRTB. The Beijing strains percentage as shown in spoligotyping was at 43%, in both MDRTB and FQR isolates was relatively higher than in the susceptible ones. The FQ resistance has its definite association with the usage of anti-TB or anti-drug in first line medical contact, subject to the mechanism of drug resistance. To investigate the reason behind, it is reckoned in this study to be rather related with the immunity of patients, or very likely with the bacteriostasis of MTB making special protein , or the misusage of medicine. There is not single prescription against TB, therefore, it is suggested to make necessary medical experiment with caution in order not to cause early FQs resistance which will increase the overload of epidemic prevention. It is also recommended to explore with earnest the experiment of medical resistance by assessing the anti-drug development so as to provide the doctors with appropriate clinical diagnosis. Conclusively, FQs should be very conscious in usage of the clinical treatment, in order not to cause resistance strains. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:40:12Z (GMT). No. of bitstreams: 1 ntu-96-R94424027-1.pdf: 9590898 bytes, checksum: aff13fe190d1768b07ced72559581d0e (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 目錄…………………………………………………………………壹
圖目錄………………………………………………………………參 表目錄………………………………………………………………肆 中文摘要………………………………………………………… …1 英文摘要…………………… ………………………………………3 第一章 序論 第一節 Mycobacterium tuberculosis(MTB)簡介…… ……5 (一) 結核病歷史與流行病學特色……………………………5 (二) 結核病發生與診斷………………………………………6 (三) 主要致病菌特性…………………………………………7 (四) 基因資訊…………………………………………………7 (五) 治療用藥………………………………… ……………8 (六) 藥物感受性試驗………………………… ……………11 (七) Isoniazid作用機制與細菌的抗藥性…………………15 (八) Rifampin作用機制與細菌的抗藥性…………… ……16 (九) Pyrazinamide作用機制與細菌的抗藥性……… ……16 (十) 其他對抗TB藥物的作用機制與細菌的抗藥性……… 17 第二節 Fluoroquinolones(FQs)與MTB的作用 (一) Fluoroquinolones簡介……………………………… 18 (二) Fluoroquinolones新舊藥比較……………………… 18 (三) Fluoroquinolones的作用目標不同………………… 19 (四) Type II topisomerase- DNA gyrase……………… 19 (五) Fluoroquinolones的作用與M.tuberculosis 基因突變的關係… 21 (六) Fluoroquinolones藥物的濃度影響…… …………… 23 第三節 M.tuberculosis抗藥菌株流行病學的分型 (spacer oligonucleotide typing -spoligotyping)24 第四節 研究目的與實驗設計 (一) 研究目的…………………………………………………27 (二) 實驗設計…………………………………………………27 第二章 研究材料與實驗方法 第一節 臨床菌株的分析 (一) 檢體來源與分佈…………………………………………29 (二) 第一線用藥抗藥性分析…………………………………29 (三) Fluoroquinolones對MTB的最小抑制濃度( MIC )分析30 第二節 突變基因的研究與流行病學的分型 (一) 突變基因的研究…………………………………… …31 (二) 流行病學的分型…………………………………… …36 第三章 實驗結果 (一) 臨床菌株的分析…………………………………… …39 (二) 突變基因的研究與流行病學的分型……………… …47 第四章 討論與結論…………………………………… …………52 第五章 附錄…………………………………… …………………58 第六章 參考文獻………………………………………………… 62 圖1 藥敏試驗…12 圖2 Isoniazid作用機制…15 圖3 Pyrazinamide作用機制…16 圖4 GyrA與GyrB之蛋白domain功能…20 圖5 DNA gyrase supercoiling cycle及DNA剪接…20 圖6 Spoligotyping原理…25 圖7 Spoligotyping判讀…26 圖8 MTB之QRDR (quinolone resistance-determining region) gyrA gene PCR,檢驗純化後的gyrA gene的存在…34 圖9 MTB之QRDR gyrB gene PCR後的產物,檢驗純化後的gyrB gene 的存在,比較PCR有沒有加DMSO的影響,GyrB PCR產物 純化後的DNA片段34-35 圖10 420個分離菌株中對fluoroquinolones、clarithromicin、 linezolid、 isepamicin最小抑制濃度(MIC)的分佈曲線圖…44 表1 治療結核病的第一線和第二線用藥…9 表2 2004年結核病在台灣用藥的準則…10 表3 抗結核菌藥物的濃度與藥敏試驗選擇濃度…14 表4 台大醫院從2000年到2006年對TB第一線用藥的抗藥情形…40 表5 420個分離菌株中對fluoroquinolones、clarithromicin、 linezolid、 isepamicin最小抑制濃度(MIC)的分佈情形…41 表6 420位TB病人在各個群組的臨床特徵…42 表7 420株M.tuberculosis的(MTB)藥物感受性結果…43 表8 420株M.tuberculosis中對任何一種fluoroquinolones類藥物呈抗藥性的有14株,與第一線用藥、過去是否用過抗TB的藥物治療,以及過去是否服用過fluoroquinolones類藥物各組中,所佔的比率比較…45 表9 Fluoroquinolones類藥物對MDR和非MDR病人的MIC50.MIC90 比較…46 表10 14株fluoroquinolones呈抗藥性的MIC分佈與gyrase基因突變位置以及是否MDR或北京株的關係…48-49 表11任何一種fluoroquinolones呈抗藥性與基因分型的關係…50 表12比較過去文獻發表與本次實驗,對fluoroquinolones 呈抗藥性分離菌株之基因型(gyrase mutation)和表現型( MIC pattern )…51 | |
dc.language.iso | zh-TW | |
dc.title | Fluoroquinolones 類藥物對結核菌抗藥性之研究 | zh_TW |
dc.title | Drug Resistance in Mycobacterium tuberculosis :
Emphasis on the Fluoroquinolones Resistance | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧麗珍,李麗娜,盧章智 | |
dc.subject.keyword | 結核病,結核桿菌,抗藥性,fluoroquinolones,DNA gyrase, | zh_TW |
dc.subject.keyword | tuberculosis,Mycobacterium tuberculosis,drug resistance,fluoroquinolones,DNA gyrase, | en |
dc.relation.page | 70 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 9.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。